Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research
A past-president of the American Spinal Injury Association, Dr. Tansey brings Lifeward over 30 years of experience in research and...
Month: September 2024
Danam Health, Inc. Announces Acquisition of Wellgistics, LLC
Tampa, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Danam Health, Inc. (“Danam”) today announced that it completed its acquisition of...
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the...
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin TIR measures approach target set...
Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training
Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot TrainingROCKAWAY, N.J., Sept. 10,...
American Burn Association Study Highlights Inequities in Access to Specialized Burn Care
Spectral AI’s DeepView® System Designed to Provide Equity in Burn Care Access While Optimizing Healthcare ResourcesDALLAS, Sept. 10, 2024 (GLOBE...
A new report from the Access to Medicine Foundation reveals how patient-focused pharma companies’ access efforts are
AMSTERDAM, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The latest report from the Access to Medicine Foundation takes a first-ever look...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for...
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
SAN DIEGO, CA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the...
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious...
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and...
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
A second shipment of 500,000 units is expected to be made by the end of OctoberLOS ANGELES, Sept. 10, 2024...
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent...
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on...
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancerThe...
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over...
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
Nanox to Participate in Upcoming Investor Conference in September 2024
PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative...
Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment...
